Fibromyalgia Rx in EULAR guidelines includes amitryptylline which won the vote and duloxetine and neurontin or gabapentin which others chose. New thinking is to decide on Rx by type of pain. Don't forget exercise, sleep hygiene, CBT #EULAR2019 @RheumNow https://t.co/XEKG6WBU1i
— Janet Pope (@Janetbirdope) June 15, 2019
Pts with RA have shame and guilt which correlates with demographics and disease activity. Something to think about, acknowledge and give proper help. FRI0030 #EULAR2019 @RheumNow
— Janet Pope (@Janetbirdope) June 15, 2019
More in #gout news from #EULAR2019: men on uric acid-lowering therapy (and only 1/3 of people in this study were) were less likely to visit the #ER than those who weren’t
— CreakyJoints.org (@CreakyJoints) June 15, 2019
Low dose steroids in RA are benign? I speak to @dr_rachelblack about cataract and glaucoma risk from steroids for @RheumNow (data from SAT0592 at #EULAR2019) https://t.co/3Qo4dZdTNK pic.twitter.com/1kLQ2VwSD3
— David Liew (@drdavidliew) June 15, 2019
BIIB059 is a monoclonal antibody that blocks BDCA2, which inhibits the production of inflammatory mediators in SLE. A Phase 1 trial showed drug to be safe& tolerable. It continues being investigated in SLE& cutaneous #lupus. #EULAR2019 #InsideLupusResearch https://t.co/bbcV3W57DD
— Lupus Foundation of America (@LupusOrg) June 15, 2019
Clinical Highlights #EULAR2019: Emapalumab, an IFN- gamma blocking monoclonal antibody, is effective in macrophage activation syndrome in patients with childhood-onset #SLE #PReS2019 @carmona_loreto >LA
— ARD & RMD Open (@ARD_BMJ) June 15, 2019
We unfortunately missed out on it at #EULAR2019 but nice work and important paper from @CCalabreseDO @cappelliMD @MarieKostine @BetsyKirch @LCalabreseDO on PMR-like irAEs. An area worth exploring! https://t.co/IrEI7QzCPZ @RheumNow
— David Liew (@drdavidliew) June 15, 2019
You can stop MTX in RA pts in low disease state after adding tofa 11 mg daily long acting for 24 Wks if CDAI <11 (Oral Shift) No diff btw continue vs D/C MTX. Some pts will be happy to stop MTX without loss of effect LBOOO4 #EULAR2019 @RheumNow
— Janet Pope (@Janetbirdope) June 15, 2019
Sjogrens EULAR guidelines leave me dry! Lots of collaboration and work on guidelines but not much content which begs for RCTs in Sjogrens to help our pts. SP0190. But some recent RCTs recently + such as Leflunomide+ Hydroxychloroquine #EULAR2019 @RheumNow pic.twitter.com/JZDcBLHai8
— Janet Pope (@Janetbirdope) June 15, 2019
For PsA poly arthritis what do you usually start
— Janet Pope (@Janetbirdope) June 15, 2019
What happens when you use very low doses for rituximab retreatment for RA? More flares, but interesting mean disease activity/B cells comparison suggest most get by fine and fewer get infections #EULAR2019 LB0010 from Nijmegen @RheumNow pic.twitter.com/opsUMPwOFd
— David Liew (@drdavidliew) June 15, 2019
RA confers a similar risk of inpatient admission for influenza as age >65yo in a large Australian general medical cohort. When will our RA patients get similar access to high dose influenza vaccine as patients >65yo do? #EULAR2019 FRI0058 @bonnialiu @earlyARA @RheumNow pic.twitter.com/hR1fYHdZzQ
— David Liew (@drdavidliew) June 15, 2019
"My confidence & zest for life back again", "Being a good mum", "Not having to think about ways to conserve energy". The #patient view of #remission involves the symptoms of the disease, as well as its manifestations. Ruth Williams at #EULAR2019 pic.twitter.com/uzaF7lXuEg
— Arthritis Ireland (@Arthritisie) June 15, 2019
Some very good & practical suggestions for how to improve function and patient #remission suggested by Ruth Williams: good continuity of care & communication; holistic approach to physio, OT & podiatry; CBT; exercise classes & simple aids. #EULAR2019 pic.twitter.com/OHxLjV7Syj
— Arthritis Ireland (@Arthritisie) June 15, 2019
Great talk from @EATC4Children Prof Ramanan on uveitis and current therapeutic options #EULAR2019 pic.twitter.com/44RuFyr1JM
— Alder Hey Research (@AHFTResearch) June 15, 2019
RheumNow expanded twitter coverage of the #EULAR2019 annual meeting is sponsored by Horizon Pharma. All content chosen by RheumNow & its Faculty.
— Dr. John Cush (@RheumNow) June 15, 2019
RA-ILD therapy: some very useful thoughts from @TobyMMaher, a respiratory expert from Royal Brompton #EULAR2019 SP0199 @RheumNow pic.twitter.com/6Y7HziX4Kc
— David Liew (@drdavidliew) June 15, 2019
Good lessons from 22,607 RA patients from the UK CPRD: cataracts and glaucoma from pred are dose dependent, and even 1000mg cumulative dose is enough. That’s equivalent to three months PMR therapy for most #EULAR2019 SAT0592 @dr_rachelblack @CatherineL_Hill @earlyARA @RheumNow pic.twitter.com/AJfBgLdHdb
— David Liew (@drdavidliew) June 15, 2019
20% of patients post-total KNEE replacement have chronic pain
vs
5% of patients post-total HIP replacementWe don’t know why @larhumato #eular2019
— Dr Irwin Lim (@_connectedcare) June 12, 2019
Does Rheumatoid Arthritis Really Improve During Pregnancy? A Systematic Review and Metaanalysis 👉🏻Disease activity improved in 60% of patients with RA in pregnancy and flared in 46.7% postpartum. https://t.co/QKun6vOzDY #EULAR2019 Thanks @montesa_maria pic.twitter.com/9QA84ITapO
— Carlo V Caballero MD (@carvicab) June 15, 2019
EULAR large vessel guidelines say if refractory GCA consider addition of Tocilizumab or MTX to steroids. Whereas in TAkayasu's you should start with immunosuppressive + steroids SP0192 #EULAR2019 @RheumNow pic.twitter.com/Sn1j5Pqzgu
— Janet Pope (@Janetbirdope) June 15, 2019
The same basic factors are in play in RA-ILD as in IPF, as are outcomes. There’s a separation between the two, but maybe things are coming back together… #EULAR2019 SP0199 Toby Maher from @RoyalBrompton @RheumNow pic.twitter.com/gUDYbDcBrZ
— David Liew (@drdavidliew) June 15, 2019
#Hyperuricemia (HUC) /#gout found to be associated with CVD in a cohort of 37,315 PsA patients. Investigators at Icahn Mt Sinai saw higher rates of Afib and HF (with preserved ejection fraction) in patients with hyperuricemia/gout vs those without. SAT0371 #EULAR2019 @RheumNow pic.twitter.com/98B3JSFSnv
— Gout Study Group (@GoutGroup) June 15, 2019
Belimumab with great safety in largest SLE RCT ever #EULAR2019 @RheumNow https://t.co/cvdX6bBtag
— Janet Pope (@Janetbirdope) June 15, 2019
Association between pre-treatment ANA and TNFi immunogenicity in RA? Very interesting, worth exploring… #EULAR2019 SAT0155 from Shinko, Kobe, Japan @RheumNow pic.twitter.com/hmUNonteq4
— David Liew (@drdavidliew) June 15, 2019